Drug intelligence / Profile preview

Flavolife liver disease senolytic

Development stage: Preclinical
Lead developer: Flavolife
Modality: Small Molecules

Overview

Flavolife's liver disease program involves an undisclosed small molecule pan-senolytic candidate. Built on a flavonoid scaffold platform, the drug is designed to selectively eliminate senescent cells, which are known to accumulate in the liver and contribute to chronic inflammation and fibrosis. By targeting senescent cell anti-apoptotic pathways (SCAPs), the molecule aims to clear these dysfunctional cells and restore tissue homeostasis. The program is currently in the discovery stage, and the specific molecular targets have not been disclosed by the developer.

Beyond the preview

Go deeper on Flavolife liver disease senolytic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flavolife liver disease senolytic.

Explore the full profile